Clin­i­cal un­cer­tain­ty, price push­es UK's NICE to spurn Akcea's Waylivra

Echo­ing some of the con­cerns the FDA un­der­scored be­fore hand­ing its re­jec­tion, the UK’s cost-ef­fec­tive­ness watch­dog NICE has al­so for­sak­en Akcea’s drug, volane­sors­en. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER